ERAS · Erasca, Inc.
$14.75
+0.01 (+0.03%)
At close · Oct 5
Return incl. dividend (before tax)
Market Cap
$4.98B
Shares
349.76M
Volume · Oct 5
5.49M
Avg daily vol (3M)
4.26M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$14.74
Open$14.81
Day$14.57–15.27
52W close$2.13–22.47
Avg vol 30d4.5M
Short int33.0M · 9.4% float · 7.7d
Short vol72%
Last earningsMay 8, 2024
DataJul 2021–Oct 2026
Filing10-Q · Aug 11
Up next
filed Aug 11, 2026
call held Mar 27, 2024
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$287.22M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-2.0%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$268.74M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+9.9%
Year over year · more shares
Price change (1Y)
+592.0%
Trailing year
Short interest
9.4%
Latest settlement · 7.7 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Buy
Momentum
Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+5%
above
Price vs 50-day avg
−13%
below
RSI (14)
42
neutral
MACD trend
Positive
52-week position
62%
mid-range
Momentum
relative strength
1-month return
−9%
trailing
6-month return
−10%
trailing
YTD return
+296%
this year
Relative strength
−22%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $17 › 200d $14 — 50d above 200d
Institutional flow
Accumulating
1 of 257 funds reported for Sep 30 · net +95 sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
9.45% of float · ▲ +5.8% MoM · 7.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
257 holders — near 3-yr high, broad support
Squeeze score
56
elevated · 0–100
Fundamentals
EPS growth
+36%
Y/Y
Free cash flow
$-95.6M
Quant / Vol
risk profile
Volatility
102%
annualized · 1-yr
Max drawdown
−59%
past year
ATR
6.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+5%
Bullish
Price vs 50-day avg
−13%
Bearish
RSI (14)
42
Neutral
MACD trend
Positive
Bullish
52-week position
62%
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $17 › 200d $14 — 50d above 200d
Institutional flow
Accumulating
1 of 257 funds reported for Sep 30 · net +95 sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
9.45% of float · ▲ +5.8% MoM · 7.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
257 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $2
Now $15 · 62%
Range high $22
vs 200-day avg +5%
vs 50-day avg -13%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filingsFigures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ERAS
this stock
Erasca, Inc.
|
$4.98B | +296.2% | — | — | 9.4% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +544.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ERAS | +3.4% | -9.4% | -9.6% | +0.6% | +296.2% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | +3.7% | -8.9% | -21.8% | -0.4% | +283.4% |